针对COPD的精确医学:针对2型细胞因子和警示因子
1Department of Translational Medical Sciences, University of Naples Federico II, Italy; Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Italy; World Allergy Organization (WAO), Center of Excellence (CoE), Naples, Italy; Institute of Experimental Endocrinology and Oncology, National Research Council (CNR), Naples, Italy.
针对2型炎症和上皮警示蛋白的向显示出治疗慢性阻塞性肺病 (COPD) 患者的一个子集的前景,有可能推进精准医学方法.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性阻塞性肺病 (COPD) 是一种全球性流行病,影响了超过45岁的10%的人.
- 慢性肺炎的特征是异质性炎症,包括中性爱好者和性爱好者表型.
- 免疫细胞和细胞因子是COPD病变的关键驱动因素和潜在的治疗点.
研究的目的:
- 调查2型 (T2) 炎症和表皮衍生的警示素在COPD中的作用.
- 评估针对COPD恶化的特定细胞因子和途径的有效性.
- 探索用于COPD治疗的精密医学方面的进展.
主要方法:
- 审查最近的随机临床试验 (RCT),评估COPD的生物疗法.
- 对针对IL-5,IL-5Rα,IL-4Rα,TSLP和IL-33通路的研究进行分析.
- 对抗TSLP,抗IL-33和抗ST2疗法的正在进行的RCT的评估.
主要成果:
- 向IL-5或IL-5Rα的生物药物显示,在eosinophilic COPD中恶化症的适度减少.
- 抗IL-4Rα疗法在COPD患者中显著减少了COPD恶化,这些患者具有高氨基酸细胞计数.
- 阻断更广泛的通路 (IL-4/IL-13) 似乎比单细胞因子抑制更有希望.
结论:
- 针对T2炎症,包括像TSLP和IL-33这样的上皮警示蛋白,为一组COPD患者提供了潜在的精准医学策略.
- 目前正在进行的试验调查炎症的上游调节剂对于未来的COPD治疗至关重要.
- 了解COPD内型对于开发有效的向疗法至关重要.
相关概念视频
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
COPD: Management Using Bronchodilators and Corticosteroids
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease-I: Introduction
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:


